ARTICLE | Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
April 8, 2013 7:00 AM UTC
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) gained $0.19 (16%) to $1.38 on Monday after receiving a preliminary comment letter from FDA that the company said "outlines a pathway" by which the biotech could submit an NDA for IV peramivir to treat influenza. BioCryst declined to disclose details.
The stock finished the week with a $0.51 (43%) gain to $1.70...